Latest Health News

Australian Foundation Investment Company plans special fully franked dividends alongside its 2026 interim and final payouts, leveraging a strong franking credit balance.

Osteopore Limited has partnered with DKSH Malaysia in a five-year agreement to distribute its innovative dental products, aiming to capture significant growth in Malaysia’s guided bone regeneration sector.

SRG Global has landed $650 million worth of contracts spanning water, defence, energy, and more across Australia and New Zealand, reinforcing its position as a diversified infrastructure leader.

Bio-Gene Technology Limited has received a $519,500 R&D tax incentive from the Australian government, supporting its development of innovative bio-insecticides targeting insecticide resistance.

Euroz Hartleys Group Limited reported a robust FY2025 with an 87.7% jump in net profit and a strong start to FY2026, driven by increased brokerage and capital markets activity.

Pro Medicus Ltd has delivered a record-breaking FY2025 with revenue soaring nearly 32% and net profit up 39%, driven by landmark contracts and a robust growth pipeline.

Metro Performance Glass reported a surprising 157% jump in net profit for H1 2025, even as revenue fell 5%, raising questions about underlying business dynamics.

Island Pharmaceuticals has secured membership in the Medical Countermeasures Coalition, positioning its antiviral Galidesivir for critical US government stockpiling and regulatory milestones.

Atomic Eagle Ltd, formerly known as Tombador Iron Limited, will have its trading suspension lifted and be reinstated to quotation on the ASX starting 24 November 2025 after meeting key compliance requirements.

The Foreign Investment Review Board has formally objected to Cosette Pharmaceuticals’ proposed acquisition of Mayne Pharma, casting serious doubt on the deal’s future and prompting Mayne to explore alternative paths.

Verbrec Limited has reported a strong FY2025 with record margins and resumed dividend payments after more than a decade, alongside strategic moves including a key acquisition and divestment.

Earlypay Limited has extended its on-market share buy-back program for another 12 months, allowing the company to repurchase up to 10% of its ordinary shares without shareholder approval.